Our ideology

Currently asthma is highly uncontrolled and its prevalence is increasing globally. Patient numbers with COPD (Chronic Obstructive Pulmonary Disease) are also increasing worldwide. This is placing a huge and growing burden on healthcare systems worldwide, including the UK’s NHS.

What is particularly sad is that young people in the UK are more likely to die from asthma than those in other wealthy countries, and as “Prevention is at the heart of the NHS Long Term Plan…” improving the devices that young asthma sufferers rely upon for their treatment will go a long way to support this.

The metered dose inhaler (pMDI) is currently the mainstay of asthma and COPD management worldwide, with approximately 940 million units produced each year.  Its design has barely changed over the 60+ years that it has been available, and it is notoriously difficult to use correctly, with over 90% of users unable to accomplish the correct technique.

Additionally, there is mounting environmental pressure to reduce the prevalence of pMDIs, due to their use of HFA (hydrofluoroalkane) propellants that directly contribute to global warming.

To solve these issues, CHI is developing its αeolus technology: a passive, high-performance dry powder inhaler (DPI) platform, which is designed to out-perform existing DPIs and improve patient outcomes through its high delivery efficiency and consistency that is independent of patient effort.

CHI have entered a collaboration with Kindeva Drug Delivery to develop and commercialise αeolus.  As a true platform technology, αeolus-driven devices may be available in multiple variants that utilize the same core technology. These variants include single-use, reusable, and multi-dose devices.

CHI has also developed a pMDI add-on device (“q-technology”) that addresses two of the major issues of using pMDIs:

  1. patients inhale too quickly
  2. patients are not able to successfully coordinate actuating the device with their inhalation.

The q-technology has been patented and has received interest from several companies who specialise in pMDIs and / or their components. It is the aim of CHI to develop this technology into a clinical prototype in time for clinical studies of new, more environmentally friendly propellants, such as HFA152a.

αeolus dry powder inhaler

Single use

  • User simply inhales to receive dose
  • Low cost (~30 cents)
  • Inherently breath-actuated


  • Load blister & inhale
  • Low cost (~40 cents)
  • Breath-actuated
  • Device replaced monthly

Multi-unit dose

  • Up to 60 unit blister doses
  • Cost ~$1.5
  • Breath-actuated
  • SMART / connected adds ~$1

All DPIs built on the αeolus platform have identical performance

q-technology – pMDI add-on device


  • Reduces plastic content
  • Reduces cost
  • Improves flowrate and timing


  • Improves flowrate
  • Improves coordination
  • Provides audible & tactile feedback


  • Improves flowrate and coordination
  • Measures inhalation flowrate profile and other valuable parameters
  • Fully connected for ~$1